Stockreport
Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina
Last caladrius biosciences inc earnings: 8/9 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: caladrius.com/investors/overview
PDF
BASKING RIDGE, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that the Company acquired from Shire plc (LSE:SHP) (NASDAQ:SHPG) an exclusive worldwide license to data from a late stage CD34+ cell therapy program for the treatment of chronic myocardial ischemia targeting refractory angina. Under the terms of the agreement, Caladrius acquired the exclusive worldwide rights to the data set and regulatory filings for the CD34+ cell therapy program for the treatment of refractory angina. In exchange, Shire will receive undisclosed up-front consideration, milestones and a royalty on product sales. The comprehensive data set that Caladrius licensed includes preclinical (in vivo and in vitro) and Phase 1, Phase 2 and Phase 3 clinical study data of CD34 cell therapy as
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CLBS | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CLBS alerts
CLBS alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLBS alerts
High impacting CALADRIUS BIOSCIENCES INC news events
Weekly update
A roundup of the hottest topics
CLBS
NEWS
NEWS
- Caladrius Biosciences Inc (NASDAQ: CLBS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.25 price target on the stock.[MarketBeat]
- Caladrius Biosciences Inc (NASDAQ: CLBS) had its price target raised by analysts at HC Wainwright to $15.00. They now have a "buy" rating on the stock.[MarketBeat]
- Caladrius Biosciences Inc (NASDAQ: CLBS) had its "buy" rating re-affirmed by analysts at Chardan Capital.[MarketBeat]
- Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference[GlobeNewswire]
- Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2018 Results - Earnings Call Transcript [Seeking Alpha][Seeking Alpha]
- More
CLBS
SEC Filings
SEC Filings
- 8/9/18 - Form 8-K
- 8/9/18 - Form 10-Q
- 8/3/18 - Form EFFECT
- CLBS's page on the SEC website
- More